Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Clinical trial NCT05950139 · RECRUITING

Trial details

NCT number: NCT05950139
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

NSCLC Stage IV ALK Fusion Protein Expression

Start date: 2024-05-13
Primary completion: 2027-07-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.